Key result
Systemic alteplase restores hemodynamics without maternal or fetal bleeding in massive PE during pregnancy.
Why the study?
Does systemic thrombolysis with alteplase improve clinical and hemodynamic outcomes in pregnant women with massive pulmonary embolism and persistent shock?
Case Report (n=1)
No
Does systemic thrombolysis with alteplase improve clinical and hemodynamic outcomes in pregnant women with massive pulmonary embolism and persistent shock?
Systemic thrombolysis with alteplase can be a life-saving and safe therapeutic option for both the mother and fetus in pregnant patients presenting with life-threatening massive pulmonary embolism.
Supports cautious use of alteplase in pregnant massive PE with shock; leaves open need for prospective safety data.
A 25-year-old pregnant woman presented at 12 weeks of gestation with syncope and shortness of breath caused by massive pulmonary embolism. Due to persistent shock, fibrinolytic therapy with rtPA was administered. After fibrinolysis, clinical and hemodynamic response was excellent. No bleeding and fetal complications were recorded.
No takes yet. Share an insight, caveat, or question.
Hoang et al. (2020) conducted a case report in Massive pulmonary embolism in pregnancy (n=1). Alteplase was evaluated on Clinical and hemodynamic response. Systemic thrombolytic therapy with alteplase resulted in excellent clinical and hemodynamic response without maternal bleeding or fetal complications in a pregnant patient with massive pulmonary embolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: